Gerresheimer’s Creditor Deal and Rejected Bid Frame a Precarious Path Forward

A crucial debt reprieve and a spurned takeover offer have defined the recent trajectory of Gerresheimer, even as the German pharmaceutical packaging specialist grapples with a deep-seated accounting scandal and rising operational costs. The company secured vital breathing room from its creditors in late March, with noteholders representing 96% of the €870 million total volume agreeing to extend deadlines until the end of September 2026. Key financial covenants related to leverage have been suspended through the third quarter of that year.

This financial flexibility arrives as the company navigates the fallout from significant accounting irregularities. An independent law firm confirmed systematic violations of IFRS rules, centered on so-called bill-and-hold agreements where revenue was booked for goods before they were shipped. These errors amounted to €35 million in revenue and €24 million in adjusted EBITDA for the 2024 financial year. The German financial regulator, BaFin, initiated a review of the interim financial statements in March 2026, examining potential misstatements in leasing liabilities (€65.5 million book value), incorrect useful lives for capitalized development costs, and unrecorded impairments in the Advanced Technologies segment (book value nearly €197 million).

Against this complex backdrop, Gerresheimer also turned down an unsolicited approach. According to a Reuters report citing three informed sources, U.S. rival Silgan made an indicative offer of €41 per share in March, more than double the trading price at the time. Talks are no longer ongoing, with management opting to pursue an independent turnaround focused on resolving its balance sheet issues and executing a strategic divestiture.

The planned sale of the U.S. subsidiary Centor is a cornerstone of that strategy. The unit, which manufactures packaging systems for prescription drugs and was carried on the books at €292 million at the end of 2024, has drawn interest from a double-digit number of parties. Morgan Stanley is advising on the process, which Gerresheimer expects to conclude within this calendar year. Proceeds are intended for debt reduction.

Should investors sell immediately? Or is it worth buying Gerresheimer?

Operational headwinds are compounding the corporate turmoil. Recent producer price data from Germany’s Federal Statistical Office showed energy costs rose 7.5% in March from February, with mineral oil products surging 22.9%. For a manufacturer of energy-intensive glass and plastic packaging, this imposes direct margin pressure. The company’s ability to pass these costs on to pharmaceutical and food customers will be critical for its target of achieving an adjusted EBITDA margin of 18-19% by the 2026 financial year, alongside revenue of €2.3-2.4 billion.

The accounting crisis has triggered wider repercussions. The audit oversight body APAS has opened a professional conduct procedure against auditor KPMG, which issued an unqualified opinion on the 2024 accounts despite the subsequently revealed errors. KPMG had only replaced previous auditor Deloitte in 2024. Shareholder association DSW is examining potential damage claims against former CEO Dietmar Siemssen and former CFO Bernd Metzner, with questions also surrounding business valuations totaling approximately €676 million.

Uncertainty continues to cloud the stock. Since the start of the year, shares have lost about 21%, with a twelve-month decline exceeding 58%. Trading around €22, the price remains roughly 66% below its 52-week high of €64.40. While an RSI of just under 31 indicates an oversold condition, annualized volatility of around 100% reflects persistent market nerves. The stock dipped briefly on the Reuters report but recovered quickly, with institutional investors like the CastleKnight Master Fund and Deka Investment reporting new positions, betting on a potential stabilization.

The immediate corporate calendar remains in flux. The Q1 report, originally scheduled for April 16, and the Annual General Meeting set for June 3 have both been postponed, with new dates pending. The company aims to present the audited annual and consolidated financial statements for 2025 in June 2026, followed by the half-year report on July 14. Until the independent special auditors deliver validated figures in June, providing clarity on the full extent of the booking errors, assessing the group’s true earning power remains a challenge for investors.